3D Cell Culture 2022 Virtual Conference

Developing complex, translatable, and physiologically-relevant cellular models in vitro

Conference Proceedings

Standard Price

US$ 616.05

Change your currency: USD EUR GBP


Standard Price

US$ 739.51

US$ 739.51

User Details

3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027, researchers globally are realising the growing potential of in vitro applications for drug discovery, predictivity and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.

Rising demand for tissue engineering for the treatment of chronic diseases is another key driver of this research -- new technologies in the form of organ-on-chip, microphysiological systems and 3D bioprinting are all burgeoning areas of the field.

Join us in February 2022, as our 5th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and biotech companies to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of applications of new technologies, and insights into 3D bioinks and high throughput screening to give a comprehensive look into this fast growing industry.

Benefits of Attending

  • DISCUSS the uses of advanced cell technologies to construct in vitro models of human tissues
  • EXPLORE the regulatory sciences surrounding Microphysiological systems, and their development and adoption for drug safety assessment
  • UNCOVER the major benefits of 3D modelling in enhancing clinical translation and predictability
  • UTILISE 3D cell culture for High Throughput drug discovery and Content screening over traditional 2D methods
  • DELVE into advanced case studies looking into organ models: from organotypic lungs to liver spheroids

Who should attend

Key Job Titles include Head of, Director, Manager of...
  • Complex in vitro models
  • Cell and molecular science
  • Disease models
  • Cell technology
  • Microphysiological systems
  • Microfluidics
  • Toxicology
  • Stem Cell Sciences
  • Tissue Engineering
  • High throughput screening
  • 3D Imaging

Plus Interactive Half Day Pre-Conference Workshops | Tuesday 8th February 2022

Workshop A: Reducing attrition in drug discovery through the use of human translational cellular models
Workshop Leader: Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
8.30 - 12.30

Workshop B: Bioprinting for 3D Cell Culture
Workshop Leader: Kenny Dalgarno, Professor of Manufacturing Engineering, newcastle university
13.30 - 17.30

Featured Speakers

  • Anne Rios, Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology
  • BanuPriya Sridharan, Investigator, GSK
  • Caroline Archer, Associate Principal Scientist, AstraZeneca
  • Catherine Vickers, Head of Innovation, NC3Rs
  • Darren Heywood, Product Manager, Promega UK Ltd
  • Elisa Budyn, Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
  • Freddy Van Goethem, Scientific Director, Fellow, Janssen (Johnson & Johnson)
  • Hansjoerg Keller, Senior Principal Scientist, Novartis Institutes for BioMedical Research
  • Isabella Bondesson, Field Application Specialist, CELLINK
  • Jason Ekert, Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline
  • Julian Bahr, Senior Scientist, AstraZeneca
  • Louis Scampavia, Scientific Director, Sr, Scripps Research
  • Luca Frenguelli, Senior Scientist, Engitix Therapeutics
  • Lyle Armstrong, CSO Newcells Biotech and Professor of Stem Cell Sciences Newcastle University, Newcells Biotech Limited
  • Pedro Pinto, Laboratory Lead, University of Greifswald – Medical Centre
  • Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA
  • Robert Vries, CEO, Hubrecht Organoid Technology
  • Stefan Przyborski, Professor, Durham University
  • Stephen J. Fey, Founder and Chief Research Officer, Celvivo
  • Suzanne Fitzpatrick, SeniorAdvisor for Toxicology, FDA
  • Terry Van Vleet, Director of Investigative Toxicology, AbbVie

Please fill in your name and email to receive the Virtual Conference Agenda of this event.


The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.

Event details
Organizer :SAE Media Group
Event type :Conference
Attendance :Online Event
Reference :ASDE-23274